``

Corona Remedies IPO Analyzed

Corona Remedies, a pharmaceutical company based in Gujarat, is planning to offer shares to the public through an Initial Public Offering (IPO). The company wants to raise approximately ₹655.37 crore. Let’s break down what you need to know about this offering.

Key Points

• Company raises ₹655.37 crore through an offer for sale (OFS).
• Existing shareholders will sell their stake, no new funds raised.
• Issue open December 8-10, 2025, anchor investor period Dec 5.
• Lot size: 14 shares, minimum investment ₹14,868.
• Listed on NSE & BSE, tentative listing December 15, 2025.
• Company’s revenue up 17.93% to ₹1,196.4 crore in FY25.

Corona Remedies was established in 2004. They focus on making medicines for women’s health, heart problems, pain relief, and issues related to the urinary system. They have a wide range of medicines, with 71 different brands covering various health areas. The company has two factories in Gujarat that can produce a lot of medicine – over 1.28 billion units each year.

The IPO will allow investors to buy shares in Corona Remedies. The offer will run from December 8th to December 10th, 2025. Investors can apply for shares one day before, from December 5th to 7th. You need to buy at least 14 shares to start. That means a minimum investment of around ₹14,868 if you buy at the highest price.

The shares will be listed on the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE). The company has tentatively scheduled a listing date of December 15, 2025. Bigshares Services is in charge of managing the IPO, along with JM Financial, IIFL Capital Services, and Kotak Mahindra Capital Company.

In the last three months ending June 30, 2025, Corona Remedies made ₹346.54 crore in sales and earned ₹46.2 crore in profit. Overall, in the last year (FY25), the company’s sales increased by 17.93% to ₹1,196.4 crore. The company also showed a significant increase in profitability, with EBITDA up 52.56% to ₹245.92 crore and profit after tax rising by 65.11% to ₹149.43 crore.

Before the IPO was officially launched, some shares of the company were traded in the unofficial market. On December 3, 2025, these unlisted shares were valued at ₹1,122, showing a premium of 5.65% compared to the expected price of the shares.

The IPO represents a significant step for Corona Remedies towards becoming a publicly traded company.

`